The analyst's Medical Devices sector report, “Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Next Generation Sequencing (NGS) Tests - Pipeline Products under Development by Companies
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4bases SA
- AccuraGen Inc
- ACT Genomics Co LTD
- Adaptive Biotechnologies Corp
- Almac Diagnostic Services Ltd
- Amoy Diagnostics Co Ltd
- AnchorDx Medical Co Ltd
- ArcherDx Inc
- Berry Oncology Corp
- BGI Genomics Co Ltd
- Biocartis Group NV
- Biodesix Inc
- BioLink
- bioTheranostics Inc
- Boston University
- Buhlmann Laboratories AG
- Burning Rock Biotech Ltd
- Cardiff Oncology Inc
- CCM Biosciences Inc
- Cerba HealthCare SAS
- Cyclomics BV
- DCGen Co Ltd
- Eiken Chemical Co Ltd
- Epic Sciences Inc
- Epigenomics AG
- FBB Biomed Inc
- Feng Biosciences Inc
- First Genetics JCS
- Flomics Biotech
- Foundation Medicine Inc
- Gencurix Inc
- GeneCast Biotechnology Co Ltd
- Geneseeq Technology Inc
- Genetron Health (Beijing) Co Ltd
- Genomic Health Inc
- GigaGen Inc
- HaploX Biotechnology Co Ltd
- Haystack Oncology Inc
- HTG Molecular Diagnostics Inc
- Illumina Inc
- Immunovia AB
- Inivata Ltd
- Insight Genetics Inc
- Invivoscribe Inc
- IvyGene Diagnostics
- Laboratory Corp of America Holdings
- Leto Laboratories Co Ltd
- Lucence Diagnostics Pte Ltd
- MedySapiens Inc
- Mega Genomics Ltd
- Micronoma
- MolecularMD Corp
- NGeneBio Co Ltd
- Novigenix SA
- Novomics Co Ltd
- NuGEN Technologies Inc
- NuProbe Inc
- Oncodiag
- OncoDNA SA
- OncoSpire Genomics
- OrigiMed Inc
- Otsuka Medical Devices Co Ltd
- Pasteur Institute
- Personal Genome Diagnostics Inc
- Pillar Biosciences Inc
- Predicine Inc
- Predictive Biosciences Inc (Inactive)
- PT PathGen Diagnostik Teknologi
- Qiagen NV
- Quantgene Inc
- Queen's University
- RealSeq Biosciences Inc
- Rhodx Inc
- Roche Diagnostics International Ltd
- SeqOne SAS
- Silicon Biosystems S.p.A.
- Sophia Genetics SA
- Sostos LLC
- Spectrum Solutions LLC
- Sysmex Corp
- Sysmex Inostics GmbH
- Tempus Health Inc
- Tempus Labs Inc
- Thermo Fisher Scientific Inc
- Trivitron Healthcare Pvt Ltd
- TwinStrand Biosciences Inc
- University of Chicago
- University of Michigan Rogel Cancer Center
- University of Texas Health Science Center at Houston
- Veracyte Inc
- Vyant Bio Inc (Inactive)